Eurofins Scientific to acquire Beacon Discovery to expand drug discovery capabilities

Eurofins Scientific, a testing laboratories company based in Luxembourg, has agreed to acquire Beacon Discovery, a drug discovery and contract research organization (CRO), engaged in the research of G-Protein Coupled Receptor (GPCR).

The financial terms of the deal were not disclosed.

The California-based Beacon Discovery will join Eurofins Discovery, a CRO that has a portfolio of validated in vitro pharmacology, ADMET, and chemistry services for drug discovery solutions.

Dr. Sunny Al-Shamma – Beacon Discovery CEO said: “Beacon Discovery is very excited to join Eurofins. Joining the Eurofins Discovery organisation expands our opportunity to continue our drug discovery efforts and provide integrated drug discovery services with the additive and complementary capabilities provided by Eurofins Discovery.”

Eurofins Scientific to acquire Beacon Discovery to expand drug discovery capabilities. Photo courtesy of mwooten from Pixabay.

Its acquisition is said to support the strategy of Eurofins Scientific to be the partner of choice to the pharma industry through its drug discovery experience, knowledge, and success in helping in the discovery and development of new therapeutics.

Beacon Discovery is also said to augment Eurofins Discovery’s capabilities and innovative methods considerably to support and expedite drug discovery research and development and exploit the growing R&D outsourcing market.

Dr. Gilles Martin – Eurofins Scientific CEO said: “Beacon Discovery adds the expertise in GPCR targets and drug discovery and development experience that will advance our offering in integrated drug discovery services for our clients. This transaction is another demonstration of Eurofins’ commitment to provide the most comprehensive portfolio of laboratory services in the discovery pharmacology field which enjoys a strong outsourcing growth trend.

The deal, which is subject to customary closing conditions, is expected to be wrapped up in the coming weeks.